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Kinases and Pseudokinases: Lessons from RAF
Andrey S. Shaw,a,b Alexandr P. Kornev,d,e Jiancheng Hu,a,b Lalima G. Ahuja,d,e Susan S. Taylorc,d,e
Department of Pathology and Immunologya and Howard Hughes Medical Institute,b Washington University School of Medicine, St. Louis, Missouri, USA; Departments of
Chemistry/Biochemistryc and Pharmacologyd and Howard Hughes Medical Institute,e University of California San Diego, La Jolla, California, USA

P

rotein kinases play important roles in the regulation of most
biological processes in eukaryotic cells, including cell growth,
differentiation, cell death, and metabolism, and their dysfunction
is associated with many diseases. They function by catalyzing the
transfer of phosphate from ATP to protein substrates. Protein
phosphorylation, in general, can modulate the activity of a wide
variety of enzymes as well as control specific protein-protein interactions. Their importance is attested to by the fact that the
mammalian genome contains over 500 different protein kinases,
constituting about 2% of all of the proteins encoded by the genome (1).
Questions about whether protein kinases function solely as
catalytic enzymes are raised by the presence of large numbers of
pseudokinases in the genome. About 10% of the 518 members of
the mammalian kinome are considered pseudokinases because
they lack one or more critical conserved kinase residues, suggesting that they lack or have impaired kinase activity (1). An even
larger percentage of pseudokinases are present in pathogens such
as Giardia and Toxoplasma (2–4). Some protein kinases originally
considered to be pseudokinases, such as WNK, CASK, and Haspin, are probably bona fide protein kinases that use variant motifs
to substitute for the absence of conventional catalytic residues
(5–7) and are probably committed to very specific substrates.
However, the large number of remaining pseudokinases suggests
that they may have a more general essential noncatalytic role in
signaling pathways. Several classification schemes have been proposed for pseudokinases and suggest that they may have distinct
mechanistic functions, with some being true catalysts with specific
dedicated substrates, others being inert scaffolds that cannot even
bind ATP, and others that bind ATP to induce a conformational
change but do not require transfer of the phosphate for their function (8, 9). A classification scheme based on differences in nucleotide binding has recently been proposed (8). Since excellent reviews on pseudokinases are available that focus on their
noncatalytic roles in signaling pathways (9–12), we will focus here
on a new way of thinking about kinase and pseudokinase regulation as driven by hydrophobic spine assembly and the potential
noncatalytic functions for bona fide kinases. Specifically, we wish
to extend ideas about pseudokinases by asking (i) do all kinases, in
fact, have bifunctional properties with both catalytic and noncata-

lytic functions, (ii) can we uncouple and independently explore
these two functions, and (iii) are both functions essential for signaling or in some cases is the noncatalytic function sufficient?
An important insight into the function of pseudokinases was
recently provided by a unifying model showing how all kinases are
dynamic molecular switches that toggle between inactive and active states (13). This switch mechanism is driven by the assembly
and disassembly of hydrophobic spines that define the core fold
and architecture of the kinase domain itself. While the specific
mechanisms underlying kinase activation are diverse and kinase
specific, assembly and disassembly of the hydrophobic spines
function as the common underlying mechanisms that drive most
regulatory mechanisms. Therefore, mutations that stabilize the
spines can be used to decipher both the catalytic and noncatalytic
functions of protein kinases. Although still largely unexplored, we
propose that the function of pseudokinases is also likely to correlate with the assembly and disassembly of their hydrophobic
spines. Our current knowledge from the RAF kinases as a model
system shows how both pseudokinases and constitutively active
kinases can be created by simple manipulation of the hydrophobic
spines. This indicates how the kinase domain itself carries an ability to function as a signaling enzyme or as an inert signaling scaffold where the actual transfer of the phosphate may not be essential.
In this review, we explore the possibility that kinases, both
conventional active kinases and catalytically inactive pseudokinases, have important noncatalytic roles as allosteric regulators
and that both the catalytic and noncatalytic functions can be interrogated independently by manipulation of the hydrophobic
spines. Analogous to the G-protein family of signal transduction
regulators, we propose that kinases are highly regulated and
dynamic molecular switches that use ATP binding and assembly
of the regulatory spine (R-spine) to induce conformational
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Protein kinases are thought to mediate their biological effects through their catalytic activity. The large number of pseudokinases in the kinome and an increasing appreciation that they have critical roles in signaling pathways, however, suggest that catalyzing protein phosphorylation may not be the only function of protein kinases. Using the principle of hydrophobic spine assembly, we interpret how kinases are capable of performing a dual function in signaling. Its first role is that of a signaling
enzyme (classical kinases; canonical), while its second role is that of an allosteric activator of other kinases or as a scaffold protein for signaling in a manner that is independent of phosphoryl transfer (classical pseudokinases; noncanonical). As the hydrophobic spines are a conserved feature of the kinase domain itself, all kinases carry an inherent potential to play both roles in signaling. This review focuses on the recent lessons from the RAF kinases that effectively toggle between these roles and can be
“frozen” by introducing mutations at their hydrophobic spines.

Minireview

changes that can engage the catalytic machinery and regulate interactions with downstream effectors. These are likely to be important,
previously unrecognized mechanisms for kinase function and regulation and have great relevance not only for understanding oncogenic
mutations but also for the design of kinase inhibitors.
KINASES TOGGLE BETWEEN INACTIVE AND ACTIVE
CONFORMATIONS

The protein kinases have evolved to be highly dynamic molecular
switches that are turned off and on rapidly in response to intracellular and extracellular cues. Typically, protein kinases are thought
to be maintained in a basal, inactive state and recruited to action
only transiently by stimuli that include binding of a growth factor
to its receptor, binding of a chemokine to a receptor, a photon of
light, or generation of a variety of second messengers. Often, activation is associated with release of an inhibitory domain. The
discovery of dynamically assembled hydrophobic regulatory
spines (R-spines) introduced a new concept for how these
dynamic molecular switches are assembled.
The first protein kinase structures of cyclic AMP (cAMP)-dependent protein kinase (PKA) revealed the conserved kinase fold
and provided functional insight for how the conserved sequence
motifs contribute to both structure and function (14). By comparing many kinase structures, in both the inactive and active conformation, Kornev et al. were able to identify two key structural elements that are assembled in every active kinase and not assembled
in every inactive kinase (13) (Fig. 1). The first structural element
that they identified was called the regulatory spine (15). This is a
stack of four hydrophobic residues that are aligned in active kinases but broken in inactive kinases. Two residues (RS1 and RS2)
come from the C-terminal lobe (C-lobe) and two (RS3/RS4) from
the N-terminal lobe (N-lobe). RS1 comes from the important
HRD sequence that precedes the catalytic loop, RS2 from the DFG
sequence that marks the beginning of the activation loop, RS3
from the ␣C-helix, and RS4 from the ␤4-strand (16). In PKA,
these residues are Y164, F185, L95, and L106, respectively. The
assembly of this R-spine illustrates how kinase activation involves
the integration of many separate components of the kinase. This
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includes not only the conserved kinase core but also, more importantly, the regions that flank the core that are often conserved in
family-specific ways.
Later, a second hydrophobic spine was identified and is referred to as the catalytic spine (C-spine) (17). Assembly of the
C-spine is mediated by the binding of ATP. The adenine ring of
ATP interacts with residues in both the N-lobe and the C-lobe and
functions to appose the two lobes and stabilize the kinase in a
relatively “closed” position, where the ␥-PO4 is positioned for
transfer to a protein substrate (Fig. 1). Binding of ATP thus engages all of the catalytic machinery and, based on nuclear magnetic resonance (NMR), creates an enzyme that is now “committed” to catalysis (18). Thus, catalysis for all active kinases involves
the binding of ATP that completes the C-spine, while regulatory
mechanisms specific to each kinase function to assemble the Rspine. Both spines are anchored to a highly unusual hydrophobic
F-helix, which horizontally spans the C-lobe (17).
While the R-spine can be broken in many ways, a common
mechanism, as seen in BRAF, is that the DFG phenylalanine actually occupies the ATP binding site (Fig. 2) (19). In this scenario,
not only is the R-spine broken but ATP binding is also blocked.
This inhibited state may be even more stable in the full-length
proteins when inhibitor domains are present. In fact, the entire
N-lobe of the kinase could be significantly rearranged in many
full-length proteins, but we have very few kinase structures that
represent full-length proteins. By studying only the kinase domain, the kinase is likely to be much more dynamic in comparison
to the fully inhibited state that exists in the full-length kinase.
Understanding the structure and dynamics of full-length kinases
is one of the next significant challenges for the structural biology
community.
Once inhibition is released, the active and inactive conformations that correlate with the assembled and disassembled R-spine
are typically in dynamic equilibrium (Fig. 3). Release of inhibition
also allows for dimerization, which is an essential step in the activation of many protein kinases, including the RAF family of kinases. Assembly of the active R-spine is typically facilitated and/or
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FIG 1 Hydrophobic catalytic and regulatory spines define the active protein kinase conformation. Using PKA as a prototypical model for the protein kinase
family, we show how the active kinase is assembled around two hydrophobic spines (left). The catalytic cycle is initiated by the binding of ATP, which completes
the C-spine and connects the ␥-phosphate of ATP with the catalytic machinery (center). This “commits” the kinase to catalysis by completing the C-spine,
whereas in the active kinase the C-spine is broken in the absence of ATP and in this case the kinase is “uncommitted” to catalysis (Apo structure, right). In the
case of pseudokinases, there is no commitment to catalysis. Simple stability of the R-spine to allow for dimerization is the endpoint. The C-spine is yellow; the
R-spine is red.

Minireview

FIG 3 Activation of Raf is initiated by the release of the inhibitory N-terminal
domain. The initial step in the activation of Raf is binding of Ras(GTP) to the
N-terminal domain, which “unleashes” the kinase domain. In the absence of
Ras(GTP), the kinase domain is locked into an inhibited state where the Rspine is assumed to be broken and, we suspect, ATP cannot bind. Unleashing
of the kinase domain allows for the dynamic toggling of the R-spine between its
assembled and disassembled state, although equilibrium most likely favors the
broken spine.
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further stabilized by phosphorylation of the activation loop (AL)
or by binding of accessory molecules such as cyclins (20, 21). Since
the DFG motif defines the beginning of the AL, repositioning of
the AL by phosphorylation would function to reposition the DFG
into its active position in the R-spine and would also establish
communication with the C-helix, allowing it to correctly align the
next R-spine residue (RS3).
The assembly of the R-spine in conjunction with C-spine assembly then results in a kinase that is primed for catalysis (Fig. 4).
While the “primed” conformation is generally thought to enhance
the catalytic activity of the kinase by facilitating the transfer of the
␥-phosphate from ATP to the substrate, the stable, “primed” conformation might also have enhanced interactions between the kinase and binding partners like substrates, other kinases, or other
scaffold proteins. The increased affinity for a substrate may enhance the efficiency of the kinase reaction, but interactions with
other cellular proteins may also have important or even essential
functions for downstream signaling. These may not be related to a
traditional kinase-substrate relationship and may not require the
transfer of the phosphate. Certainly, efficiency of phosphotransfer
is not a requirement for kinases. They have not evolved to be
efficient enzymes but rather have evolved to be succinct regulated
enzymes. Indeed, increasing kinase catalytic activity often creates
an oncogene (22). Therefore, release of inhibition is likely to be far
more important for regulating kinase function than catalytic efficiency.
KINASES ARE SLOW ENZYMES

The efficiency of enzymes can be judged by their turnover rate
(kcat), the maximum number of substrate molecules they can convert to product per catalytic cycle per unit of time. The fastest
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FIG 2 Activation of BRAF is mediated by assembly of the regulatory spine. In the inactive BRAF (right), the R-spine is broken, whereas the R-spine is assembled
in the active BRAF (left). The BRAF numbering here does not count the initiator methionine. Note the movement of F594, part of the DFG motif, which is
displaced in the inactive kinase (right). In the absence of the inhibitory N-terminal domain, the kinase will toggle between these two states, with equilibrium most
likely favoring the disassembled spine.

Minireview

allows the BRAF R-spine to toggle between its inactive (broken) and active (assembled) conformations. While dimerization and AL phosphorylation shift the
equilibrium to favor the assembled R-spine, it is the binding of ATP that assembles the C-spine, allowing interactions between the R-spine and C-spine to prime
the kinase for catalysis. The primed active conformation of the kinase is important for both bona fide kinases and pseudokinases, but in the pseudokinase this is
the endpoint; there is no subsequent catalysis.

known enzymes, so-called perfect enzymes, have turnover rates
close to 600,000/s. This means they can turn over 600,000 substrate molecules to product in 1 s. The majority of enzymes, however, are much slower, with average turnover rates of about 10 to
20/s (23). Among the slowest of the enzymes are the protein kinases that have turnover rates that range from 0.05 to 1.0/s. This is
in the same range as the GTPases, which are typically thought of as
switches and not enzymes (24, 25). Since the normal time scale of
signaling reactions is in the seconds to minutes range, the ability of
kinases to phosphorylate more than one downstream substrate
may also be very limited.
The ability of protein kinases to phosphorylate more than one
substrate is based on in vitro solution studies where substrate,
typically a small peptide, is not limiting. However, protein kinases
in cells worked on tethered proteins, not peptides, and do not
typically function under these Michaelis-Menten conditions. Our
greater understanding of the role for scaffolds that function to
tether substrates close to kinases and phosphatases suggests, for
example, that, in vivo, access to substrate might not be diffusion
limited (26). Targeted access to specific substrates and slow turnover suggest that a single turnover (a single perfect catalytic cycle)
may be more important in kinase function than turning over large
amounts of substrate. Certainly, in some cases this will be true.
The efficiency of kinase-inactivating mechanisms like dephosphorylation by phosphatases further limits the ability of kinases to
phosphorylate more than one substrate. The slow enzymatic rate
for kinases is another reason to consider that noncatalytic functions of kinases could also be important in signaling pathways and
suggests that we need to reevaluate the idea that kinase cascades
function mainly for signal amplification.
VRK, MLKL, STRAD, AND ERBB3 PSEUDOKINASES AS
ALLOSTERIC ACTIVATORS

Another reason to think about the noncatalytic roles of kinases in
signaling is suggested by recent data regarding the role of pseudokinases in signaling pathways. As noted above, kinases lacking
conserved residues required for catalytic activity are classified as
pseudokinases. Several pseudokinases have now been shown to
function noncatalytically as allosteric activators.
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VRK3. Vaccinia-related kinase (VRK) is a family of kinases
that contain two active kinases, VRK1 and VRK2, and a pseudokinase, VRK3. VRK1 and VRK3 are found in the nucleus, while
VRK2 is found in the endoplasmic reticulum. VRK3 is structurally
similar to VRK2 but lacks the ability to bind to ATP, because
hydrophobic side chains fill the adenine binding pocket. It is thus
a naturally occurring bona fide pseudokinase in which the C-spine
is fused by hydrophobic residues that fill the adenine binding
pocket; it is nevertheless fixed in an active-like conformation (27).
In addition, the N-terminal linker is docked onto the glycine loop
and further restricts binding of ATP. The crystal structure of
VRK3 shows that both spines are assembled in an active-like but
inert conformation (Fig. 5) (27, 28). It is thus a truly dead pseudokinase. VRK3 functions by binding of a mitogen-activated protein kinase (MAPK) phosphatase, vaccinia H1 related (VHR), and
enhancing its phosphatase activity, and this function does not
require catalytic activity.

FIG 5 Vrk3, an example of a true pseudokinase. The structure of Vrk3 reveals
that it is a true pseudokinase (catalytically inactive), because it cannot bind
ATP but is locked into an “active-like” conformation where the R-spine is
assembled. Several of the residues near the ATP binding pocket (shown in tan
on the left), including two C-spine residues, are replaced with larger hydrophobic residues, and these fill the adenine binding site, causing the C-spine to
fuse. ATP, drawn in black, is sterically blocked from binding. The two assembled spines (C-spine in yellow and R-spine in red) are shown on the right. The
overall Vrk3 structure in the middle shows several reasons why it is an inert
pseudokinase: the adenine binding site is filled with hydrophobic side chains
(1), the glycine loop is shorter than other protein kinases (2), and the N-terminal tail, shown in teal, is locked onto the glycine loop (3).
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FIG 4 Binding of ATP to the C-spine primes the assembled hydrophobic R-spine for catalysis. Using the analogy of an oscillating pendulum, release of inhibition

Minireview
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domain is dimerized with another member of the EGF receptor
family. The detailed mechanism whereby dimerization of the extracellular ligand binding domain then mediates dimerization and
activation of the cytoplasmic kinase domain in the full-length EGF
receptor is still a great challenge for the signaling community (36).
ERBB3 is a kinase-impaired pseudokinase, but when heterodimerized, it is a potent activator of signaling (37, 38).
Dimerization of another EGFR family member with ERBB3 can
allosterically activate the kinase activity of the catalytically active
partner (39). The current model is that ligand binding to any of
the receptors of this family generate homo- and heterodimers, and
dimerization then allows for allosteric activation (39, 40). Attesting to its importance, ERBB3 mutations are present in over 10% of
tumors (41). While many of the mutations are in the extracellular
domain and presumably promote dimerization of the extracellular EGF binding domain, some of the mutations are in the kinase
domain, suggesting that the allosteric function of ERBB3 is also
regulated. The ligand independence of all of these mutants suggests that conformational changes in the ERBB3 kinase domain
promote dimerization and allosteric activation. How the spines
specifically contribute to these conformational switch mechanisms has not been addressed. Interestingly, certain ATP analogs
based on quinazoline can induce dimerization of the EGFR kinase
domain in cells, suggesting that ATP binding and other conformation changes may be involved in promoting dimerization
(42–44).
RAF KINASES DEMONSTRATE THE CATALYTIC AND
NONCATALYTIC FUNCTIONS OF A PROTEIN KINASE

It is now becoming clear that even bona fide kinases have functions that are independent of their catalytic activity. The RAF kinases are good examples that have been clearly shown to have
noncatalytic signaling activities (45). The surprising finding that
drug inhibitors of the BRAF serine/threonine kinase could, in certain situations, activate RAF in cells led to new insights that
showed that inhibited BRAF kinases can dimerize and allosterically activate other members of the RAF family of kinases (46–48).
For the remainder of this review, we will summarize the evidence
for noncatalytic functions for RAF and then discuss the potential
implications of this work to our general understanding of kinase
function.
The RAF family of kinases includes ARAF, BRAF, and CRAF.
Mutations in BRAF but not other forms of RAF are important in
cancer. Thus, there has been great clinical interest in understanding their function and regulation. While BRAF-specific drugs efficiently inhibit the kinase activity of a mutated form of BRAF that
is constitutively active, these drugs also paradoxically activate RAF
in cells containing wild-type (WT) BRAF and constitutively active
RAS (46–48).
As indicated in Fig. 3 and 6, the activation of the RAFs includes
several steps (49). The small GTPase, RAS, initiates the process
that leads to the activation of the MAP kinase extracellular signalregulated kinase (ERK) through an upstream kinase cascade that
includes RAF and MEK. RAF kinases are ⬃75- to 90-kDa proteins
with a regulatory domain at the N terminus and the kinase domain
at the C terminus. The N-terminal domain (NTD) contains an
RAS binding domain (RBD), and binding to RAS at the membrane leads to the release of the inhibitory NTD from the kinase
domain (Fig. 3). Supporting a role of the NTD as an inhibitory
domain, removal of the NTD can generate oncogenic forms of
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MLKL. Mixed-lineage kinase domain-like (MLKL) is a pseudokinase that functions to regulate programmed necrosis mediated by the inflammatory cytokine tumor necrosis factor alpha
(TNF-␣). Normally, signaling by TNF receptor 1 (TNFR1) functions to activate caspase 8 to stimulate apoptosis. Caspase 8 also
cleaves the RIP kinases (RIPK1 and RIPK3) to block the regulated
necrosis pathway. When caspase 8 activation is blocked by microbial proteins like viral FLIP proteins, RIP3 kinase phosphorylates
MLKL to stimulate necrosis. The structure of full-length mouse
MLKL confirms that it is a pseudokinase and shows that the catalytic lysine (K219) coordinates with a glutamine residue (Q343)
that is in an unusual helix in the activation loop preventing the
lysine from coordinating with the conserved glutamate in the ␣Chelix (29). Certain mutated catalytically inactive forms of MLKL
induced constitutive cell death, suggesting that RIP3 kinase phosphorylation of MLKL functions to induce a conformational
change that allows it to induce cell necrosis (29). The recently
solved structure of human MLKL shows an active-like conformation, with assembly of the R-spine mediated by coordination of
the catalytic lysine with a glutamic acid in the ␣C-helix (30). It is
interesting to speculate that the two structures represent active
and inactive forms of MKLK, but functional studies are necessary
to confirm this. Nevertheless, the evidence supports the idea that
MLKL toggles between an active and inactive conformation.
STRAD␣. STE20-related adapter (STRAD␣) is a pseudokinase
regulator of the kinase LKB1, which is an upstream activator of
AMPK and the AMPK family of kinases (31). This is another example of a pseudokinase that functions through its active-like
conformation. When STRAD and accessory molecule Mo25 bind
to LKB1, this results in the activation of LKB1. STRAD can bind to
ATP but lacks critical catalytic residues, including the aspartate in
the critical DFG motif. Biochemical studies support that STRAD is
a catalytically inactive pseudokinase, as it does not appear to have
kinase or ATPase activity (32). Kinase-inactivating mutations do
not impair the functional properties of STRAD, but ATP binding
is required for STRAD function.
Structural studies demonstrate that STRAD binding to Mo25
and nucleotide binding help it to be stabilized in an active-like
conformation (33). In its “active-like” conformation, STRAD
binds to LKB1. The binding of the STRAD-Mo25 complex to
LKB1, in turn, induces the active conformation of LKB1, allowing
it to be active in the absence of activation loop phosphorylation;
mutation of potential AL loop phosphorylation sites does not impair LKB1 activation by STRAD. STRAD is in the family of Ste20
kinases, which also include the PAK, HPK1, GCK, GLK, and HGK
kinases. Interestingly, it has been proposed that the function of
other Ste20-related kinases may be independent of their kinase
activities (34).
ERBB3. ERBB3 is an example of a transmembrane receptor
pseudokinase that is a member of the epidermal growth factor
(EGF) family of receptors that include ErbB1-4 (also known as
HER1-4). The prototypical receptor in this family is the epidermal
growth factor receptor (EGFR; ERB1 or HER1), which is a transmembrane protein that binds to its ligand, EGF. The EGFR family
members (except for ErbB2) bind to ligands that include EGF,
tumor growth factor alpha (TGF-␣), and the neuregulins (35).
When bound to their ligands, they form extracellular heterodimers with other EGF receptor family members. ErbB2 is
thought to function in a dimerization competent state, and its
kinase activity is stimulated when the extracellular EGF binding

Minireview

RAF (49). Release of the NTD initiates the activation process by
“unleashing” the kinase domain and allowing it to dynamically
toggle between inactive and active conformations, a process that is
driven by the assembly and disassembly of the R-spine. “Unleashing” of the kinase domain also allows for dimerization, which
shifts the equilibrium in favor of the assembled R-spine. The released kinase domain can also bind ATP, whereas in its inhibited
state, we predict that ATP will not be bound to the full-length
RAF. This will need to be tested. In the case of the RAFs, two
additional steps are required after the kinase domain is “un-

FIG 7 The C- and R-spines can be manipulated to control the active conformation of kinases. Replacing the conserved C-spine residues, Ala70 (PKA), with Phe
fuses the C-spine so that ATP cannot bind. Ala70 (PKA) normally lies on top of the adenine ring. Substitution with Ala70 with Phe (shown on the left in teal)
abolishes ATP binding and by locking the kinase in the active conformation can lead to dimerization and allosteric activation of wild-type RAF. Replacing the
equivalent R-spine residue (L95-PKA) of BRAF or CRAF (L505 and L397, respectively) with Phe (shown in teal on the right) helps to stabilize the R-spine,
resulting in a constitutively active form of RAF that is independent of Ras, dimerization, and activation loop phosphorylation. This diagram also shows how
assembly of the R-spine positions the ␣C-helix and the activation loop to achieve the active conformation. The arrows in the middle panel show the positions of
the two spine residues in the assembled spines.
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FIG 6 The active conformation of RAF is facilitated by dimerization and
activation loop phosphorylation. Ras binding releases the N-terminal inhibitory domain, allowing the R-spine to toggle between the inactive and inactive
conformations (as shown by the stacked red balls). Dimerization helps to
stabilize the active conformation of the R-spine and facilitates cis autophosphorylation of its activation loop. Once activation loop phosphorylation occurs, the kinase can maintain the active conformation of the R-spines as a
monomer, but this is rapidly reversed by active phosphatase.

leashed,” dimerization with another RAF molecule and phosphorylation of the activation loop (AL) (Fig. 6).
Mutation of a C-spine residue in BRAF creates a pseudokinase that functions as an allosteric activator of WT BRAF and
CRAF. Previously, it was shown that certain oncogenic forms of
BRAF were either kinase inactive or kinase impaired (45). Also we
had previously shown that mutation of a C-spine residue in BRAF
(A481F) blocked catalytic activity but resulted in a form of BRAF
that constitutively dimerized and activated ERK (50). In this case,
because Ala481 is a C-spine residue that lies directly on top of the
adenine ring, the phenylalanine ring most likely fills the adenine
pocket, similar to what is seen in VRK3 (Fig. 5 and 7), and this is
sufficient to unleash the N-terminal inhibitory domain. Because
downstream activation of MEK and ERK still required dimerization, we concluded that the A481F BRAF mutant was functioning
as a kinase-inactive allosteric activator. Formation of the dimer
with a wild-type BRAF did indeed induce autophosphorylation of
the partner RAF, and because the activator could not bind ATP,
we surmised that this must occur by cis autophosphorylation. Our
next challenge was to understand why the same mutation in CRAF
also induced dimerization but did not activate ERK. Truncation
experiments with BRAF revealed that the major difference was in
a segment that just precedes the beginning of the kinase domain,
and this was confirmed by mutations of this region in both BRAF
and CRAF (51).
Requirements for dimerization. Just N-terminal to the kinase
domain is a conserved acidic motif (NtA) that is part of the dimer
interface. A functional equivalent to this motif may be conserved
in other kinases, including the EGF receptor and the Src and ITK
family of kinases (39, 52–54). These flanking segments, which are
typically quite dynamic, can be thought of as “capping” motifs
that help to organize and activate the kinase core. In BRAF, the
NtA (SSDDW) has two serine residues that are constitutively
phosphorylated plus two acidic aspartic acids, so that this se-
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phorylation are of two types. The first is based on the assumption
that trans phosphorylation requires dimerization and utilizes dilution as an argument for validation. If the autophosphorylation
reaction attenuates with dilution, this is used as evidence in favor
of trans autophosphorylation. The other assumption here is that
that cis autophosphorylation occurs only with monomeric kinases, which would not attenuate with dilution. The second, more
definitive proof uses a catalytically inactive form of the kinase as
the substrate. If phosphorylation of the activation loop of the
“dead” kinase occurs, this is strong proof for trans autophosphorylation. Most of the evidence in the literature, however, is based on
dilution experiments. A dilution experiment is not sufficient to
distinguish between cis and trans phosphorylation.
Until now, cis autophosphorylation of the activation loop has
been thought to be relatively rare and reported for only a few
kinases, like DYRK (56), glycogen synthase kinase 3␤ (GSK-3␤)
(57, 58), p38␣ (59), and Fus3 (60), although the precise mechanism for cis autophosphorylation is not well understood. For
some kinases, like the DYRK family of kinases, cis autophosphorylation is thought to occur during biosynthesis. In other cases, it is
binding of an accessory molecule that induces AL autophosphorylation. Hsp90 binding to GSK3-␤ (57), TAB1 binding to p38␣
(59), and Ste5 binding to Fus3 are required for cis autophosphorylation to occur (60). Importantly, the requirement of an accessory protein demonstrates that dimerization (in this case with a
nonkinase partner) is still a requirement for cis autophosphorylation. In the case of RAF, the accessory protein is RAF itself. The
presence of a phosphorylated NtA domain allows the activator
molecule to induce the active conformation of the receiver and in
the process allows the receiver to cis autophosphorylate its activation loop. Whether all of these examples use accessory proteins to
drive R-spine assembly and subsequent AL phosphorylation remains to be established. However, a dilution experiment would
also attenuate cis autophosphorylation if binding of a secondary
accessory protein was required. Many of our current assumptions
about cis and trans autophosphorylation thus need to be reconsidered.
The mechanism for allosteric activation by the C-spine mutants of BRAF requires dimerization and results in phosphorylation of the activation loop of the receiver kinase. Since the activator kinase with the C-spine mutation is catalytically inactive,
autophosphorylation of the activation loop by RAF dimers most
likely occurs by cis autophosphorylation. When a kinase-inactive
form of BRAF dimerizes with a WT CRAF molecule, we could
detect induced activation loop phosphorylation only on CRAF
and not on the kinase-inactive BRAF. While it is conceivable that
the formation of higher-order clusters such as tetramers or octamers could allow for trans autophosphorylation, it is difficult to
explain why in these structures only the activation loop of the
active kinase would be phosphorylated. We favor the simplest
explanation, that allosteric activation induces cis autophosphorylation of the partner.
This has implications for the function of other predicted pseudokinases, which could function as allosteric activators even
though they are inactive as catalysts. For example, the ErbB2/
EGFR dimer (39, 40, 61), the JAK kinases where the pseudokinase
domain of JAK interacts with and regulates the bona fide kinase
domain of JAK (62), or the STRAD/Mo25 binding to AMPKK (32,
33) could potentially induce cis autophosphorylation, helping to
stabilize the active conformation.
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quence is always acidic (55). When BRAF dimerizes with another
RAF molecule, the presence of BRAF’s acidic NtA is required to
induce formation of the R-spine and phosphorylation of the activation loop on the partner kinase. If the NtA motif in BRAF is
mutated to Ala, it no longer functions as an activator even though
it can still dimerize (51). Thus, this “capping motif,” the acidic
NtA, is a key feature that allows for allosteric activation.
Phosphorylation of the equivalent NtA on CRAF (SSYYW)
and ARAF (SGYYW) occurs only during or after RAF is activated.
This explains why the C-spine mutation in CRAF is not sufficient
to generate an allosteric activator. However, substituting acidic
residues for the NtA motif in CRAF does allow the catalytically
inert form of CRAF to function as an allosteric activator. These
studies demonstrate convincingly that the RAF kinases have an
important noncatalytic, activating function.
The allosteric function of the kinase is distinct from its catalytic
activity. A mutated form of BRAF or CRAF with alanine residues
substituted for the NtA, for example, can still be allosterically activated by activator forms of BRAF and CRAF (51). In the resting
cell, since BRAF is the only RAF kinase with a constitutively phosphorylated NtA, when it dimerizes, it will transactivate the partner
RAF kinase regardless of whether the partner kinase has an acidic
NtA or not. Thus, BRAF, even inactive BRAF, can activate CRAF;
however, CRAF cannot activate BRAF until it is phosphorylated
on its NtA motif. This explains why pharmacologic inhibitors that
preferentially target BRAF allow for CRAF activation and suggests
that drugs that inhibit CRAF in addition to BRAF may minimize
problems with paradoxical activation. It also potentially explains
the function of the pseudokinase KSR in the regulation of this
pathway (51).
Mutation of the R-spine can hijack the entire regulatory
pathway. The essential step in activation of any kinase is the assembly of the R-spine, which in turn positions the ␣C-helix to
facilitate transfer of the ␥-phosphate from ATP to a protein substrate. Because it activates the kinase, allosteric activation of RAF
via dimerization must function by assembling the R-spine in the
receiver kinase. Can we replicate this by directly mutating the
R-spine? Constitutive assembly of the BRAF R-spine could indeed
be induced by mutating an R-spine residue (Leu505) to Phe,
which generated a constitutively active kinase that no longer required dimerization (51) (Fig. 7). Unlike the WT kinase where the
spine is destabilized by dephosphorylation of the AL, this mutant
does not require AL phosphorylation and is thus also phosphatase
resistant. As the mutant also does not require binding to RAS,
formation of the active conformation is sufficient to “unleash” the
inhibitory domain, similar to the C-spine mutation. This R-spine
mutant thus hijacks the entire regulatory pathway and creates a
stable active kinase that is capable of downstream activation of
MEK and ERK.
cis autophosphorylation of kinases—a function of allostery.
Most kinases require phosphorylation of the activation loop to
achieve full activation, and in many cases activation loop phosphorylation is achieved by kinase dimerization. The simplest
model for activation loop phosphorylation is trans phosphorylation, with one kinase phosphorylating the activation loop of the
dimerization partner when the two kinases are brought together.
This could occur between two different kinases, for example, MEK
phosphorylation of ERK, or could be mediated by two identical
kinases (SRC autophosphorylation).
Experimental data used to support models of trans autophos-
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The large number of pseudokinases in the kinome seems to be telling
us that the enzymatic activity of protein kinases is not the only thing
that kinases can do. Clearly, in some cases the catalytic activity is not
essential for function. Here, we suggest that the assembly of the active
R-spine functions in the regulation of both pseudokinases and catalytic kinases. The fact that the R-spine residues can toggle between
active and inactive states and that kinases in their active state can bind
to some substrates with higher affinity suggests that protein kinases
may function in a manner that is similar to how we currently view
small GTPases. Small GTPases toggle between their GTP-bound and
their GDP-bound states. They are most stable in their inactive GDPbound state, while in their active GTP-bound state, they can bind,
recruit, and activate downstream effector molecules. The half-life of
the active GTP-bound protein is controlled by the intrinsic GTPase
activity of the G-protein that is potentiated by interactions with
GTPase-activating proteins (GAPs). In the absence of GAPs, the GTP
turnover is ⬍1/s, while this is accelerated in the presence of GAPs (up
to 15/s). Thus, the time scale of G-protein activation is similar to the
time scale of kinase activity. In the case of the kinase, the GAP would
be the allosteric activator and the terminating signal would be the
phosphatase; however, the essential features of a switch are conserved. Another difference is that the substrate for the GTP-bound
enzyme is water, whereas the substrate for a protein kinase is usually
another protein.
Because kinases have catalytic activity and bona fide substrates,
the focus has always been on their enzymatic activity. The dimer
activation mechanisms described here show that there are at least
two functionally important states for any kinase. First are the substrate complexes where the active kinase is bound to and phosphorylates a substrate. The dimer activation mechanism provides a
new way of thinking about allosteric activator-receiver complexes,
where a kinase could function as an allosteric activator. Both are
likely to be biologically relevant. Here, we suggest that the mechanisms of kinase regulation are also likely to be relevant in the
regulation of pseudokinases. The discovery of the hydrophobic
spines and the mechanisms that regulate their assembly will likely
be useful as tools to probe the functional consequences of the
inactive and active states of both kinases and pseudokinases. It also
suggests that stabilization of the inactive conformation of a pseudokinase or targeting the dimer interface might allow us to think
of pseudokinases as viable drug targets.
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